A phase 2 open-label trial is now underway in Rwanda as the country seeks to contain further local spread. This past weekend, the Washington, DC-based Sabin Vaccine Institute delivered an additional 1,000 doses of a vaccine in development to the Rwandan capital of Kigali, amid the country’s first-ever recorded outbreak of Marburg virus.

Read the latest developments on Marburg — in this edition of Outbreak Insider.

Blog Resources

Popular Blogs